BDRX (Biodexa Pharmaceuticals) Total Inventories: $0.00 Mil (As of Dec. 2025)


BDRX Biodexa Pharmaceuticals PLC BDRX
45 GF Score
Price $2.61
GF Value $2.26
View Full Analysis

What is Biodexa Pharmaceuticals Total Inventories?

Biodexa Pharmaceuticals BDRX 45 Total Inventories is $0.00 Mil as of Dec. 2025. GuruFocus rates BDRX with a GF Score™ of 45/100 and a GF Value™ of $2.26.

Biodexa Pharmaceuticals's total inventories for the quarter that ended in Dec. 2025 was $0.00 Mil. Biodexa Pharmaceuticals's average total inventories from the quarter that ended in Jun. 2025 to the quarter that ended in Dec. 2025 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Biodexa Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was $5.29.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Biodexa Pharmaceuticals's Days Inventory for the six months ended in Dec. 2025 was 0.00.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Biodexa Pharmaceuticals  (NAS:BDRX) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Biodexa Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is

Net-Net Working Capital Per Share (Q: Dec. 2025 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(11.424+0.75 * 0.047+0.5 * 0-9.068
-0-0)/0.452
=5.29

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Biodexa Pharmaceuticals's Days Inventory for the six months ended in Dec. 2025 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2025 )/Cost of Goods Sold (Q: Dec. 2025 )*Days in Period
=0/3.074*365 / 2
=0.00

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Biodexa Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2025 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2025 ) / Average Total Inventories (Q: Dec. 2025 )
=3.074 / 0
=N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Biodexa Pharmaceuticals's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Biodexa Pharmaceuticals Total Inventories Related Terms

Biodexa Pharmaceuticals Total Inventories Historical Data

* Premium members only.

The historical data trend for Biodexa Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biodexa Pharmaceuticals Total Inventories Chart

Biodexa Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Biodexa Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BDRX
45GF Score
Biodexa Pharmaceuticals PLC BDRX
Total Inventories is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biodexa Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Frequently Asked Questions Learn more about Total Inventories →
What does a Total Inventories of $0.00 Mil mean?
Biodexa Pharmaceuticals (BDRX) has a Total Inventories of $0.00 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for Biodexa Pharmaceuticals and its competitors.
Is Biodexa Pharmaceuticals' Total Inventories too high?
Biodexa Pharmaceuticals' current Total Inventories is $0.00 Mil. Overall, Biodexa Pharmaceuticals has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Biodexa Pharmaceuticals' Total Inventories compare to CASIF and OGEN?
Biodexa Pharmaceuticals' Total Inventories of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Biodexa Pharmaceuticals and its competitors. Biodexa Pharmaceuticals's current Total Inventories is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biodexa Pharmaceuticals stock overvalued right now?
Biodexa Pharmaceuticals (BDRX) has a current Total Inventories of $0.00 Mil. The stock's GF Value™ is $2.26, compared to a current price of $2.61 — trading 15.5% above its estimated fair value. The current Total Inventories is $0.00 Mil. Biodexa Pharmaceuticals' overall GF Score™ is 45/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Biodexa Pharmaceuticals (BDRX), the current Total Inventories is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biodexa Pharmaceuticals (BDRX) Overvalued in 2026?

Based on GuruFocus' analysis, Biodexa Pharmaceuticals stock appears to be overvalued. The current stock price of $2.61 is trading 15.5% above its estimated GF Value™ of $2.26.

Key valuation signals for BDRX:

  • Total Inventories: $0.00 Mil
  • GF Value™: $2.26 vs. price of $2.61 (15.5% above fair value)
  • GF Score™: 45/100

No single metric tells the full story. See the BDRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biodexa Pharmaceuticals Business Description

Address 1 Caspian Point, Caspian Way, Cardiff, GBR, CF10 4DQ
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
45GF Score

Get the complete analysis for BDRX

Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.61
Price
$2.26
GF Value